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Objective: This study was designed to investigate the frequency of the endothelial nitric oxide
synthase (eNOS, E298D) and cytochrome P450 2J2 (CYP 2J2 50 G/T) gene polymorphisms
among Egyptian hypertensive subjects.
Subjects and methods: Genomic DNA was isolated from peripheral blood samples collected from
123 hypertensive cases and from 429 healthy non-related controls by using Magna pure system
(Roche Molecular Biochemicals, Mannheim, Germany). DNA was used to determine the frequency
of eNOS, E298D and CYP 2J2 50 G/T allelic variants using the Light Cycler polymerase chain
reaction (Realtime PCR) technique. Genotype (wild type, mutant and heterozygous) was deter-
mined by melting curve analysis.
Results: Regarding the study of eNOS and CYP2J2 gene polymorphisms, analysis of total
hypertensive cases exhibited higher frequency of mutant eNOS heterozygous ED genotype com-
pared to controls, yet statistically insigniﬁcant (27.6% vs. 21.1%, OR= 1.5, 95% CI = 0.9–2.8,
p= 0.1). Similarly, analysis of hypertensive cases also exhibited higher frequency of mutant
CYP2J2 50 GT genotypes compared to controls that was also statistically insigniﬁcant (13.8%
vs. 10.7%, OR= 1.3, 95% CI = 0.7–2.4, p= 0.4). All subgroups of hypertensive complicated.com, ahmedali@qumed.edu.
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Association of eNOS (E298D) and CYP2J2 (50 G/T) gene polymorphisms with hypertension among Egyptian cases 235cases either with cardiac diseases, with diabetic or with renal disorders showed insigniﬁcant differ-
ence compared to controls.
Conclusion: The present study demonstrated no association between eNOS E298D and CYP2J2
50 G/T gene polymorphisms and hypertension among Egyptian subjects.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian German Society for Zoology.Introduction
Hypertension is a multifactorial and polygenic disorder where
several susceptible genes interact with the environmental fac-
tors. In spite of several investigations have reported evidence
for the role of genes in the determination of blood pressure lev-
els and hypertension, the identities of the involved genes re-
main controversial. (Burchard et al., 2003; Mountain and
Risch, 2004).
Recently, multiple studies have involved variation within
eNOS and CYP2J2 genes in the blood pressure regulation,
the development of hypertension, diabetes, cardiac, obesity,
and renal complications in different ethnic regions (Wu
et al., 1996; King et al., 2005; Polonikov et al., 2008; Wang
et al., 2010). Thus the current research postulated that both
genes are candidate in the development of hypertension.
Endothelial NOS (eNOS) – one of three isoforms of nitric
oxide synthase – known as nitric oxide synthase 3 (NOS3) or
constitutive NOS (cNOS), is an enzyme that in humans is en-
coded by the NOS3 gene (Marsden et al., 1992). eNOS (NOS3)
gene is mapped to Chromosome 7 (7q35–7q36) (Marsden
et al., 1993).
However NO is generated from L-arginine by three consti-
tutive enzymes, which provide low levels of basal NO produc-
tion in a Ca2+ dependent fashion (Moncada and Higgs, 1993;
Stuehr, 1997). Endothelial NO is considered an important ath-
eroprotective mediator, as defects in the generation of nitric
oxide are contributed with increase in cardiovascular risk fac-
tors (Vallance et al., 1989).
The hypothesis that genetic variability of the eNOS gene
could lead to hypertension through a decrease in the transcrip-
tion level of the gene or a decreased enzymatic activity caused
by a change in the amino acid sequence of the encoded enzyme
was tested by several groups. In this regard a number of gene
polymorphisms have been estimated for eNOS gene (Marsden
et al., 1993) but common polymorphism determined in nucle-
otide 894 G-T leads to the substitution of aspartate instead
of glutamate at codon 298. The Asp298 variant has been dem-
onstrated to have a shorter half-life in endothelial cell culture
as the result of increased enzymatic cleavage (Ja´chymova´ et al.,
2001). In addition, clinical studies have shown that vascular
responsiveness is mutated in subjects with this variant, as
Asp298 patients have an increased vasoconstrictive response
to phenylephrine (Shimasaki et al., 1998) in agreement with de-
creased NOS activity. Thus, the Asp298 variant has been
implicated as an impact factor for both coronary disease
(Miyamoto et al., 1998; Granath et al., 2001) and hypertension
(Lacolley et al., 1998; Ja´chymova´ et al., 2001).
CYP2J2 is one of the regulatory Human cytochrome P450
enzymes, which activates the arachidonic acid to form active
epoxyeicosatrienoic acids (EETs) that are powerful endoge-
nous vasodilators, therefore playing a role in blood pressure
regulation and associating to the etiology of essentialhypertension (Sinal et al., 2000; Imig et al., 2002). It is encoded
by the CYP2J2 gene which has been located at chromosome 1
(1p31.3–p31.2) (Ma et al., 1998). Polymorphic variants of the
CYP2J2 gene is potent constrained except for its proximal pro-
moter in which there is a relatively common and functionally
relevant SNP, indicated by 50 G/T polymorphism. A high
degree of different CYP2J2 expression among different popu-
lations has been determined due to associated genetic polymor-
phisms (Wolf et al., 1990; Wu et al., 1996).
The aim of the current study is to investigate the association
of eNOS E298D and CYP2J2 50 G/T gene polymorphisms
with hypertension among Egyptian subjects.
Subjects and methods
As a pilot study ahead of a future wide scale genetic analysis of
hypertensive subjects, a convenient sample of 123 cases (83
males and 40 females) was selected for the study. These cases
were known to have hypertension i.e. with systolic blood pres-
sure (SBP) between 140 and 200 mmHg, or diastolic blood
pressure (DBP) between 90 and 120 mmHg. The minimum
duration of hypertension was one year that was conﬁrmed dur-
ing at least two visits at the outpatient clinic of Mansoura Uni-
versity Hospital. Of these cases, 22.8.3% had a positive family
history of hypertension, 28.5% had a positive parental consan-
guinity, 10.6% were smokers, 71.5% were obese and 39% had
type 2 diabetes. For comparison, 429 normal healthy unrelated
subjects (227 males and 202 females) were taken from the same
locality as controls.
Cases were furthermore grouped according to the associa-
tion of other complications into 4 subgroups including: Gp
I: hypertension with obesity: 88 (71.5%), Gp II: hypertension
with diabetes 48 (39%), Gp III: hypertension with cardiac
complication: 76 (61.8%) and Gp IV: hypertension with renal
insufﬁciency 22 (17.9%). Obesity was diagnosed on the basis of
the deﬁnitions established by the World Health Organization
(WHO) in 1997 and published in 2000, that deﬁnes the body
mass index (BMI) of obesity as being 30 or greater (WHO,
2000). On the other hand, other complications were diagnosed
by investigations including Echocardiography and lab tests for
renal function assessment.
DNA extraction and ampliﬁcation
The isolation of genomic DNA was done on a MagNA Pure
LC instrument (Roche Molecular Biochemicals, Mannheim,
Germany), using the manufacturer’s standard protocol.
Oligonucleotide primers (eNOS E298D rs1799983 gATgATCC
CCTAgAACTC; 50 G/T CYP 2J2 rs890293 ggTCCAAg
CAggTCCCgCCTCgCTCCCA) and ﬂuorescence-labeled
hybridization probes were designed for ampliﬁcation and
sequence-speciﬁc detection of corresponding polymorphism
(TIB MolBiol, Berlin, Germany). The master mixture
236 A.A.A. Ali et al.contained 2 ll of a 10· mixture of Light Cycler Fast-Start
DNA master hybridization probes (Roche Diagnostics),
5 mM MgCl2, and 0.075 lM (3 pmol/1 ll) of speciﬁc primers.
Fluorescence curves were analyzed with the Light Cycler soft-
ware (version 3.5.3). The ﬂuorescence of each capillary was
measured at wavelengths of 640 and 705 nm (dual-color op-
tion). Each result was conﬁrmed by the speciﬁc peak in the cor-
responding melting curve (Figs. 1–4).
Statistical analysis
Statistical analysis was done using the SPSS software program
version 17. Allelic and genotypic frequencies were compared
and statistically analyzed using the Fisher’s exact test and
Odds ratio (OR) with 95% conﬁdence intervals (95% CI).
Conformity of genotype distributions with Hardy–Weinberg
(HW) equilibrium was evaluated by Chi-square analysis. For
all tests, a p-value <0.05 was considered to be statistically
signiﬁcant.Fig. 1 RealTime PCR ﬁgure revealed the melting peaks of eNOS p
‘‘NC’’, positive controls ‘‘PC’’, wild type ‘‘WT’’, mutant ‘‘MT’’ and h
Fig. 2 RealTime PCR ﬁgure revealed the melting peaks of CYP2J2
control ‘‘NC’’.Results
Hypertensive cases showed higher frequency of mutant hetero-
zygous eNOS (ED) genotypes compared to total controls
(27.6% vs. 21.7%, OR= 1.5 (0.9–2.8)), yet statistically insig-
niﬁcant (p= 0.1). On the contrary, hypertensive cases showed
less frequency of dominant eNOS (DD) genotypes compared
to total controls (72.4% vs. 75.7% OR= 0.8, 95%
CI = 0.5–1.2), but also statistically insigniﬁcant (p= 0.3).
Also, all subgroups (obese cases, diabetic cases, cardiac cases
and renal cases) showed no signiﬁcant (p> 0.05) difference
of studied genetic variants compared to controls. However,
the frequency of mutant heterozygous genotype (eNOS ED)
was higher in all subgroup cases compared to controls (Ta-
ble 1). On the other hand, hypertensive cases also showed high-
er frequency of mutant CYP2J2 50 GT genotypes compared
to controls (13.8% vs. 10.7%, OR = 1.3, 95% CI = 0.7–2.4),
yet it did not reach a statistical signiﬁcance (p= 0.4). Simi-
larly, all subgroup cases showed no signiﬁcant differenceolymorphism for one running including 28 cases, negative control
eterozygous ‘‘HT’’.
polymorphism for one running including 28 cases, and negative
Fig. 3 (A) Melting peak of eNOS wild type (at 53 C), (B) melting peak of eNOS ‘‘mutant’’ (at 60 C), and (C) two melting peaks of
eNOS ‘‘Heterozygous’’.
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polymorphisms (Table 2).
Discussion
This work exhibited higher frequency of mutant heterozygous
eNOS (ED) genotypes among a pilot sample of Egyptian hyper-
tensive cases compared to controls, in spite of being statistically
insigniﬁcant particularly when associated with obesity and dia-
betes or when complicated with cardiac and renal disorders.
Thus, these results do not support the assumption that the
eNOS E298D polymorphism associates to the genetic suscepti-
bility to hypertension with or without diabetes and obesityamong Egyptian subjects. Similarly, multiple studies reported
that eNOS E298D polymorphism failed to conﬁrm an associa-
tion with hypertension among different populations: in a pop-
ulation-based cohort of Caucasians (Khawaja et al., 2007), in
Anglo-Celtic whites (Benjaﬁeld and Morris, 2000), in Pakistani
(Srivastava et al., 2008) and in Japanese (Kishimoto et al.,
2004). Moreover, meta-analysis by Zintzaras et al. (2006) also
conﬁrmed the ‘‘no association’’ of the eNOS E298D polymor-
phism with either hypertension status or blood pressure levels
in other populations.
Conversely, there are studies that demonstrated a positive
association of eNOS E298D with hypertension in a Caucasian
population (Lacolley et al., 1998), in Korean (Lustberg et al.,
Fig. 4 (A) Melting peak of CYP2J2 wild type (at 65 C), (B) melting peak of CYP2J2 ‘‘mutant’’ (at 57 C), and (C) two melting peaks of
CYP2J2 ‘‘Heterozygous’’.
238 A.A.A. Ali et al.2001), in Japanese (Tsujita et al., 2001), in Chinese (Tang et al.,
2008) and in male Asian Indians (Srivastava et al., 2008).
This study also demonstrated a higher frequency of mutant
CYP2J2 GT genotype among hypertensive cases compared to
normal controls that was statistically insigniﬁcant. This high
frequency was grouped among cases associated with obesity,
diabetes, cardiac and renal complications. In agreement to
our ﬁndings, other studies have failed to show the association
as those done among Caucasian and African American subjects
(Pucci et al., 2003; Dreisbach et al., 2005). Nonetheless, in
contrast to these ﬁndings, previous studies have also pro-
vided evidence for an association between CYP2J2\7 (50 G/T) polymorphism and hypertension as those done among: Cau-
casian males (King et al., 2005), Han Chinese (Wu et al., 2007),
Russian subjects (Polonikov et al., 2008) and Saudi subjects
(Alghasham et al., 2012). Another interesting point of this work
is the ﬁnding of 7% of healthy controls being carriers of the mu-
tant CYP2J2\7 allele, a ﬁgure comparable to that found among
Japanese (6.21%), in Ovambo people (6.72%) (Takeshita et al.,
2008), in Chinese (2.6%) (Wang et al., 2006), and in Caucasians
(7.7%) (King et al., 2005), but higher of that described among
Mongolians (3.39%) (Takeshita et al., 2008) and Korean sub-
jects (4.23%) (Lee et al., 2005) and less than what was found
among Asian (13%) (King et al., 2002), and African-American
Table 1 eNOS E298D gene polymorphism among cases of hypertension compared to controls.
eNOS E298D genotypes eNOS E298D alleles
EE ED DD n E D
n (100%) n (%) n (%) n (%) n (100%) n (%) n (%)
Controls n= 429 325 (75.7) 93 (21.7) 11 (2.6) 858 743 (86.8) 115 (13.2)
Cases n= 123 89 (72.4) 34 (27.6) 0 (0.0) 246 212 (86) 34 (13)
p 0.3 0.1 0.1 0.7 0.7
OR
(95% CI)
0.8
(0.5–1.2)
1.5
(0.9–2.8)
0 0.9
(0.6–1.4)
1.1
(0.7–1.7)
Diabetic cases n= 48 32 (66.7) 16 (33.3) 0(0.0) 96 80 (83.3) 16(16.7)
p 0.2 0.07 0.4 0.4 0.4
OR
(95% CI)
0.6
(0.3–1.2)
1.8
(0.85–3.4)
0.0 0.8
(0.4–1.4)
1.2
(0.7–2.3)
Cardiac cases n= 76 54 (71.1) 22 (28.9) 0 (0.0) 152 130 (86) 22 (14)
p 0.4 0.2 0.2 0.8 0.8
OR
(95% CI)
0.8
(0.5–1.4)
1.5
(0.9–2.5)
0.0 0.9
(0.6–1.5)
1.1
(0.7–1.8)
Renal cases n= 22 16 (7.7) 6 (27.3) 0 (0.0) 44 38 (86) 6(14)
p 0.8 0.6 1.0 1.0 1.0
OR
(95% CI)
0.8
(0.3–2.2)
1.4
(0.5–3.6)
0.0 0.98
(0.4–2..4)
1.0
(0.4–2.5)
Obese controls n= 318 244 (76.7) 67 (21.1) 7 (2.2) 636 555 (87) 81 (13)
Obese cases n= 88 61 (69.4) 27 (30.6) 0 (0.0) 176 149 (85) 27 (15)
p 0.2 0.06 0.2 0.4 0.4
OR
(95% CI)
0.7
(0.4–1.2)
1.7
(0.98–2.8)
0.0 1.8
(0.5–1.3)
1.2
(0.8–8.2)
Table 2 CYP2J2 gene polymorphism among cases of hypertension compared to controls.
CYP2J2 genotypes CYP2J2 alleles
GG GT TT n G T
n (100%) n (%) n (%) n (%) n (100%) n (%) n (%)
Controls n= 429 376 (87.6) 46 (10.7) 7 (1.6) 858 798 (93) 60 (7)
Cases n= 123 105 (85.4) 17 (13.8) 1 (0.8) 246 227 (92.3) 19 (7.7)
p 0.5 0.4 0.7 0.8 0.8
OR
(95% CI)
0.8
(0.5–1.5)
1.3
(0.7–2.4)
0.5
(0.06–4.1)
0.9
(0.5–1.5)
1.1
(0.7–1.9)
Diabetic cases n= 48 41 (88.6) 6 (9.1) 1 (2.3) 96 88 (91.7) 8 (8.3)
p 0.8 0.8 1 0.7 0.7
OR
(95% CI)
0.8
(0.4–1.9)
1.2
(0.5–2.95)
1.3
(0.2–10.7)
0.8
(0.4–1.8)
1.2
(0.6–2.6)
Cardiac cases n= 76 65 (85.5) 10 (13.2) 1 (1.3) 152 140 (92.1) 12 (7.9)
p 0.7 0.6 1 0.8 0.8
OR
(95% CI)
0.8
(0.4–1.7)
1.3
(0.6–2.6)
0.8
(0.1–6.6)
0.9
(0.5–1.7)
1.1
(0.6–2.2)
Renal cases n= 22 17 (77.3) 5 (22.7) 0 (0.0) 44 39 (88.6) 5 (11.4)
p 0.2 0.09 1 0.4 0.4
OR
(95% CI)
0.5
(0.2–1.4)
2.4
(0.9–6.9)
0 0.6
(0.2–1.5)
1.7
(0.6–4.5)
Obese controls n= 318 284 (89.3) 29 (9.1) 5 (1.6) 636 597 (93.9) 39 (6.1)
Obese cases n= 88 80 (93.2) 7 (6.8) 1 (2.3) 176 167 (94.9) 9 (5.1)
p 0.7 0.8 1 0.7 0.7
OR
(95% CI)
1.2
(0.5–2.7)
0.9
(0.4–2)
0.7
(0.1–6.2)
1.2
(0.6–2.6)
0.8
(0.4–1.7)
Association of eNOS (E298D) and CYP2J2 (50 G/T) gene polymorphisms with hypertension among Egyptian cases 239(14.1%) subjects (Takeshita et al., 2008). The conﬂicting results
of the CYP2J2 gene in hypertension and other diseases mightbe due to the different demographic and ethnic factors of sam-
pled subjects. Therefore, conﬁrmation of these ﬁndings in a
240 A.A.A. Ali et al.wide scale study including other populations might be war-
ranted. Such controversial associations lead us to believe that
these conclusions are limited by diverse factors challenging hu-
man geneticists involved in the multifactorial disease research.
It is relevant to recognize that disease prevalence is a
consequence of the intersection of the genetic variation that
represents a population with the possible histories of environ-
mental exposures. Each population is expected to have a differ-
ent distribution of relative genotype frequencies and a different
constellation of possible environmental histories (Sing et al.,
2003).
In conclusion, this study demonstrated that there was no
signiﬁcant association between eNOS E298D and CYP2J2
50 GT gene polymorphisms and hypertension whether being
complicated or not among studied Egyptian subjects. In this
respect, we recommend – in order to clarify the signiﬁcance
of this gene polymorphism – that it is necessary to perform a
large-scale study and prospective cohort study with increased
number of subjects to more accurately judge association of
the polymorphism with hypertension. Future research should
preferentially focus on gene–environment interactions as well
as haplotype analyses.
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